Previous 10 | Next 10 |
2024-05-10 07:22:21 ET More on Akero Therapeutics Akero Therapeutics' EFX Data Warrants Caution Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program Akero Therapeutics announces pricing of stock offering to raise $319M Akero stock jumps as lead ...
-- Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported during the first quarter of 2024 -- -- Phase 3 SYNCHRONY Histology and SYNCHRONY Real-World studies in patients with pre-cirrhotic MASH (F2-F3) continue to en...
SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management wil...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Akero To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - May 7, 2024) - Faruqi & Faruqi, LLP, a leading national securi...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Akero To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - May 5, 2024) - Faruqi & Faruqi, LLP, a leading national securi...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 in Akero to Contact Him Directly to Discuss Their Options New York, New York--(Newsfile Corp. - May 2, 2024) - Faruqi & Faruqi, LLP, a leading national securi...
2024-04-30 08:34:29 ET More on Akero Therapeutics Akero Therapeutics' EFX Data Warrants Caution Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program Read the full article on Seeking Alpha For further details see: Akero Therapeutics names Sco...
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today announced the appointment of Scott Gangloff as Chief Technology Officer. ...
(NewsDirect) Investors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it's easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class of drugs was originally designed to manage blood sugar levels in diabetics but was...
2024-04-19 17:10:14 ET More on ContraVir Seeking Alpha’s Quant Rating on ContraVir Historical earnings data for ContraVir Financial information for ContraVir Read the full article on Seeking Alpha For further details see: Hepion ends Phase ...
News, Short Squeeze, Breakout and More Instantly...
Akero Therapeutics Inc. Company Name:
AKRO Stock Symbol:
NYSE Market:
Akero Therapeutics Inc. Website:
2024-07-09 15:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 10:00:04 ET Edward Nash from Canaccord Genuity issued a price target of $56.00 for AKRO on 2024-06-12 07:44:00. The adjusted price target was set to $56.00. At the time of the announcement, AKRO was trading at $23.43. The overall price target consensus is at $...
SAN DIEGO, CA / ACCESSWIRE / June 11, 2024 / Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Akero Therapeutics, Inc. (NASDAQ:AKRO) common stock between September 13, 2022 and October 9, 2023, all dates inclusive (the...